SUPPLEMENTARY DATA

In-Text Appendix 1. Study Investigators

Hélène Affres, Michel Alix, Françoise Archambeaud, Zina Barrou, Bernard Bauduceau, Philippe Beau, Sonia Beltran, Christelle Benoit, Jean-Paul Beressi, Gilles Berrut, Florence Bernachon, Catherine Berne, Aude Blaimont, Jean- Frédéric Blickle, Mireille Boda-Buccino, Jérôme Bohatier, Philip Böhme, Lyse Bordier, Kamel Bouchou, Benjamin Bouillet, Florence Bouilloud, Rolande Bouix, Eric Boulanger, Isabelle Bourdel-Marchasson, Catherine Bourgon, Emmanuelle Bourrinet, Patrice Brocker, Isabelle Bruckert, Corine Capet, Claire Carette, Bertrand Cariou, Agnès Carreau, Catherine Chaillou Vaurie, Samir Chamouni, Cécile Ciangura, Carole Collet-Gaudillat, Marie-Emmanuelle Combes-Moukhovsky, Thierry Constans, Muriel Cordonnier, Alain Cuperlier, Delphine Dambre, Jacques D'Avigneau, Philippe De Botton, Vincent Degros, Florence Delamarre-Damier, Serge Denat, Françoise Desbiez, Bernard Deumier, François Dorey, Jean Doucet, Eric Dresco, Anne Drutel, Eric Du Rosel De Saint Germain, Danièle Dubois-Laforgue, Béatrice Duly-Bouhanick, Olivier Dupuy, Laurent Dusselier, Samir Faucher-Kareche, Salha Fendri, Pierre Fontaine, Sophie Galinat, Armelle Gentric, Henri Gin, F. Glaise, Thierry Godeau, Béatrice Gonzalez, Isabelle Got, Bruno Guerci, Pierre-Jean Guillausseau, Samir Hadjadj, Yassine Hadjali, Marie Halbron, Serge Halimi, Charles Halter, Hélène Hanaire, Véronique Hardy, Agnès Hartemann-Heurtier, Jean-Pierre Haulot, Fanny Hequet, Michel Issa-Sayegh, Philippe Jan, Nathalie Jeandidier, Hélène Joseph-Henri, Ingrid Julier, Véronique Kerlan, Tania Kharitonnoff, Miriam Ladsous, Laure Lahaxe, Marie-Pierre Larmaraud, Elisa Lassenne, Jean-Michel Lecerf, Pierre Lecomte, Isabelle Leroux, Sandra Lesven, Marc Levy, Stéphanie Lopez, Maria Matta, François Makiza, Patrick Manckoundia, Caroline Marquis Pomeau, Hervé Mayaudon, Sophie Micheli, Réginald Mira, Florent Monnier, Helen Mosnier-Pudar, Adjoa-Sika Nassouri, Nathalie Neri, Isabelle Normand, Marc Paccalin, Corinne Pagu, Dominique Paris-Bockel, Alfred Penfornis, Jean-Luc Perie, Jean-Michel Petit, Gwenaelle Petit Aubert, Brigitte Pichot-Duclos, Linda Pivois, Marc Popelier, Géraldine Poulingue, Mathieu Priner, Valérie Quipourt, Manase Rasamisoa, Peggy Renoult-Pierre, Jean-Louis Richard †, Vincent Rigalleau, Nathalie Roudaut, Caroline Sanz, Franck Schillo, Jean-Marie Serot, Djamal Sifi, Serge Sirvain, Anissa Slimani, Emmanuel Sonnet, Catherine Sosset, Areski Soualah, Aniela Stroea, Igor Tauveron, José Timsit, Muriel Tschudnowsky, Anne Vambergue, Odile Verier-Mine, Christiane Verny, Marie Virally †.

©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-1437/-/DC1

SUPPLEMENTARY DATA

Supplementary Table S1. Patients at inclusion depending on their follow-up over 5 years

	Population n=987	Lost to Follow-up n=131 (13.3%)	Died or Completed n=856 (86.7%)	P (Lost vs. Others)	Died n=207 (21.0%)	Completed n=649 (65.8%)	P (Died vs. Completed)
Age (year)	77 [73–80]	77 [73–81]	77 [73–80]	0.28	79 [75–83]	76 [73–79]	<0.0001
Men/Women	473 (47.9) / 514 (52.1)	49 (37.4) / 82 (62.6)	424 (49.5) / 432 (50.5)	0.01	112 (54.1) / 95 (45.9)	312 (48.1) / 337 (51.9)	0.13
BMI (kg/m²)	29.3 [26.0–32.8]	28.7 [25.7–32.0]	29.4 [26.1–32.9]	0.11	29.4 [25.4–32.9]	29.3 [26.4–32.9]	0.48
Waist-to-Hip Ratio >1 men or >0.8 women	673 (68.2)	98 (74.8)	575 (67.2)	0.08	126 (60.9)	449 (69.2)	0.03
Alcohol consumption	318 (32.2)	39 (29.8)	279 (32.6)	0.52	85 (41.1)	194 (29.9)	0.003
Tobacco consumption	36 (3.6)	4 (3.1)	32 (3.7)	0.99	7 (3.4)	25 (3.9)	0.76
High School	180 (18.2)	22 (16.8)	158 (16.0)	0.60	32 (15.5)	126 (19.4)	0.67
Institutional living	38 (3.9)	3 (2.3)	35 (4.1)	0.32	14 (6.8)	21 (3.2)	0.03
Hypertension	884 (89.6)	117 (89.3)	767 (89.6)	0.92	187 (90.3)	580 (89.4)	0.69
Systolic blood pressure (mmHg)	140 [128-150]	140 [127-151]	140 [128-150]	0.91	140 [130-150]	140 [128-150]	0.83
Diastolic arterial pressure (mmHg)	73 [67-80]	75 [70-80]	73 [67-80]	0.22	71 [65-80]	74 [68-80]	0.14
Orthostatic hypotension	292 (29.6)	38 (29.0)	254 (29.7)	0.88	65 (31.4)	189 (29.1)	0.53
Cholesterol Risk Factor	871 (88.2)	107 (81.7)	764 (89.3)	0.11	182 (87.9)	582 (89.7)	0.48
LDL cholesterol (g/L)	0.90 [0.70-1.20]	1.00 [0.75-1.24]	0.92 [0.71-1.14]	0.080	0.94 [0.74-1.15]	0.91 [0.71-1.13]	0.54
Triglycerides (g/L)	1.20 [0.90-1.70]	1.26 [0.85-1.81]	1.22 [0.90-1.63]	0.68	1.21 [0.92-1.77]	1.22 [0.88-1.61]	0.49
HbA1c (%)	7·3 [6·7–8·1]	7·3 [6·7–8·1]	7·3 [6·7–8·1]	0·86	7·4 [6·8–8·2]	7·3 [6·7–8·1]	0·26
Duration of Diabetes (year)	16 [10–25[	17 [8–24[	16 [10–25[	0.33	15.5 [10–25[	16 [10–25[	0.99
HbA1c (mmol/mol)	56.3 [49.7–65.0]	56.3 [49.7–65.0]	56.3 [49.7–65.0]	0.86	57.4 [50.8–66.1]	56.3 [49.7–65.0]	0.26
Fasting blood glucose (mmol/L)	7.2 [6.1–9.4[	7.2 [6.1–8.9[	7.2 [6.1–9.4[	0.79	7.2 [6.1–10.0[	7.2 [6.1–9.4[	0.61
Capillary glucose controls/week	14 [5–21[	14 [3–21[	14 [6–21[	0.09	14 [3–21[	14 [7–21[	0.19
Hypoglycaemia last 6 months	333 (33.7)	52 (39.7)	281 (32.8)	0.12	62 (30.0)	219 (33.7)	0.31
Hyperosmolarity	3 (0.3)	1 (0.8)	2 (0.2)	0.35	1 (0.5)	1 (0.2)	0.43
Ketosis	9 (0.9)	1 (0.8)	8 (0.9)	0.99	2 (1.0)	6 (0.9)	0.99
Retinopathy	246 (24.9)	29 (22.1)	217 (25.4)	0.43	52 (25.1)	165 (25.4)	0.93
Macular oedema	33 (3.3)	7 (5.6)	26 (3.0)	0.19	8 (3.9)	18 (2.8)	0.43
MDRD <60 mL/min	215 (21.8)	27 (20.6)	188 (22.0)	0.73	73 (35.3)	115 (17.7)	<0.0001
Rhythms dysfunction	67 (6.8)	8 (6.1)	59 (6.9)	0.74	30 (14.5)	29 (4.5)	<0.0001
Conduction abnormality	219 (22.2)	24 (18.3)	195 (22.8)	0.25	59 (28.5)	136 (21.0)	0.02
Peripheral neuropathy	278 (28.2)	40 (30.5)	238 (27.8)	0.52	79 (38.2)	159 (24.5)	0.0001
Amputation	20 (2.0)	1 (0.8)	19 (2.2)	0.50	12 (5.8)	7 (1.1)	0.0003
History of Infection	129 (13.1)	18 (13.7)	111 (13.0)	0.81	36 (17.4)	75 (11.6)	0.03
Associated disease	235 (23.8)	30 (22.9)	205 (23.9)	0.79	70 (33.8)	135 (20.8)	0.0001
ADL <6	258 (26.1)	36 (27.5)	222 (25.9)	0.71	91 (44.0)	131 (20.2)	<0.0001
IADL <14	548 (55.5)	66 (50.4)	482 (56.3)	0.20	154 (74.4)	348 (50.5)	<0.0001
Cognitive disorders *	260 (26.3)	38 (29.0)	222 (25.9)	0.46	77 (37.2)	145 (22.3)	<0.0001
Screening MNA<14	503 (51.0)	81 (61.8)	422 (49.3)	0.008	126 (60.9)	296 (45.6)	0.0001
Mini-GDS >0	233 (23.6)	30 (22.9)	203 (23.7)	0.84	56 (27.1)	147 (22.7)	0.19
At least one Oral Antidiabetic Drug	699 (70.8)	92 (70.2)	607 (70.9)	0.87	133 (64.3)	474 (73.0)	0.02
Metformin	483 (48.9)	66 (50.4)	417 (48.7)	0.72	70 (33.8)	347 (53.5)	<0.0001
A-glucosidase inhibitor	49 (5.0)	4 (3.1)	45 (5.3)	0.28	13 (6.3)	32 (4.9)	0.45
DPP IV inhibitor	99 (10.0)	21 (16.0)	78 (9.1)	0.014	12 (5.8)	66 (10.2)	0.057
Glitazones	72 (7.3)	12 (9.2)	60 (7.0)	0.38	11 (5.3)	49 (7.6)	0.27
Glinides	144 (14.6)	14 (10.7)	130 (15.2)	0.17	43 (20.8)	87 (13.4)	0.010
Sulfonylureas	282 (28.6)	39 (29.8)	243 (28.4)	0.74	51 (24.6)	192 (29.3)	0.17
GLP1 analogues	47 (4.8)	7 (5.3%)	40 (4.7%)	0.74	12 (5.8%)	28 (4.3%)	0.38
GLP1 analogues or OAD	704 (71.3%)	92 (70.2%)	612 (71.5%)	0.77	136 (65.7%)	476 (73.3%)	0.03
Insulin	568 (57.5%)	72 (55.0%)	496 (57.9%)	0.52	131 (63.3%)	365 (56.2%)	0.07
Statins	622 (63.0)	67 (51.1)	555 (64.8)	0.0025	124 (59.9)	431 (66.4)	0.09

Values are number (%) or median [IQR]; * MMSE<25 or dementia

©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-1437/-/DC1

SUPPLEMENTARY DATA

Supplementary Figure S1. Survival over five years in 987 patients with infarction (red line), angina pectoris (yellow line) or without coronary heart disease (blue line); (P=0.0019)



Supplementary Figure S2. Survival over five years in 987 patients with clinical (red line), reversible or subclinical (yellow line) or without vascular disease of the cerebral vessels (blue line); (P=0.071)



©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-1437/-/DC1

SUPPLEMENTARY DATA

Supplementary Figure S3. Survival over five years in 987 patients with clinical (red line), subclinical (yellow line) or without vascular disease of the lower limbs (blue line); (P<0.0001)



Supplementary Figure S4. Survival over five years in 987 patients with foot wounds (red line) or without foot wound (blue line); (P<0.0001)



©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-1437/-/DC1